Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Taurolidine Lock Solution. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures. This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.
Primary outcome measures
- To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit]
Secondary outcome measures (11)
- Describe nurses' perceptions of their own knowledge regarding the use of taurolidine lock solutions. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Describe the medical care provided by home service providers for patients receiving a PICC placement for parenteral nutrition supplementation. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Describe the supply chain for taurolidine lock solutions. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Describe the elements related to PICC placement. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Characterize the functional status of the PICC over time. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Describe complications related to PICC placement. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Describe the causes of premature PICC removal. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Describe adverse events related to the use of taurolidine lock solutions. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Describe the difficulties encountered by healthcare professionals when using taurolidine lock solutions. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Describe the information sources used by healthcare professionals regarding taurolidine lock solutions. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
- Characterize the use of device vigilance in the event of adverse events related to taurolidine lock solutions. [Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.]
Eligibility criteria
Inclusion criteria
- Patient who has undergone PICC placement in the vascular access unit with an indication for parenteral nutrition supplementation.
- Patient not opposed to participating in this research.
Exclusion criteria
- Patient not speaking French
- Patient under guardianship or conservatorship
- Patient with major neurocognitive disorders
- Patient with severe hearing impairment
- Patient who do not have a telephone
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07259421 · 38RC25.0315.